Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **CRISPR–Cas target sequence** is a short, user-selected segment of DNA (or, in specific Cas systems, RNA) in a cell’s genome that is recognized through base pairing with the guide RNA of a CRISPR–Cas system and subsequently cleaved or edited by the associated Cas protein[2][6][7][8]. The target sequence must be adjacent to a specific short motif (the PAM sequence for most Cas systems), and its precise genetic context is selected according to experimental or therapeutic objectives. The sequence itself is not a biological entity, but rather a designation for any site that is intentionally targeted for genome engineering. Safety and efficacy of targeting depend heavily on the specificity of guide RNA design and the molecular context of cleavage.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CRISPR–Cas target sequence (null).